A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs JNJ 61393215 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen-Cilag
- 23 Dec 2016 Status changed from recruiting to completed.
- 14 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
- 24 Aug 2016 Status changed from not yet recruiting to recruiting.